Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 203
Filtrar
Mais filtros

Intervalo de ano de publicação
1.
Europace ; 24(11): 1809-1823, 2022 11 22.
Artigo em Inglês | MEDLINE | ID: mdl-36036670

RESUMO

AIMS: While mexiletine has been used for over 40 years for prevention of (recurrent) ventricular arrhythmias and for myotonia, patient access has recently been critically endangered. Here we aim to demonstrate the effectiveness and safety of mexiletine in the treatment of patients with (recurrent) ventricular arrhythmias, emphasizing the absolute necessity of its accessibility. METHODS AND RESULTS: Studies were included in this systematic review (PROSPERO, CRD42020213434) if the efficacy or safety of mexiletine in any dose was evaluated in patients at risk for (recurrent) ventricular arrhythmias with or without comparison with alternative treatments (e.g. placebo). A systematic search was performed in Ovid MEDLINE, Embase, and in the clinical trial registry databases ClinicalTrials.gov and ICTRP. Risk of bias were assessed and tailored to the different study designs. Large heterogeneity in study designs and outcome measures prompted a narrative synthesis approach. In total, 221 studies were included reporting on 8970 patients treated with mexiletine. Age ranged from 0 to 88 years. A decrease in ventricular arrhythmias of >50% was observed in 72% of the studies for pre-mature ventricular complexes, 64% for ventricular tachycardia, and 33% for ventricular fibrillation. Electrocardiographic effects of mexiletine were small; only in a subset of patients with primary arrhythmia syndromes, a relative (desired) QTc decrease was reproducibly observed. As for adverse events, gastrointestinal complaints were most frequently observed (33% of the patients). CONCLUSIONS: In this systematic review, we present all the currently available knowledge of mexiletine in patients at risk for (recurrent) ventricular arrhythmias and show that mexiletine is both effective and safe.


Assuntos
Arritmias Cardíacas , Mexiletina , Humanos , Recém-Nascido , Lactente , Pré-Escolar , Criança , Adolescente , Adulto Jovem , Adulto , Pessoa de Meia-Idade , Idoso , Idoso de 80 Anos ou mais , Mexiletina/efeitos adversos , Arritmias Cardíacas/induzido quimicamente , Fibrilação Ventricular , Eletrocardiografia , Ventrículos do Coração
2.
Europace ; 24(9): 1504-1511, 2022 10 13.
Artigo em Inglês | MEDLINE | ID: mdl-35851797

RESUMO

The aim of the study was to systematically review evidence on the effectiveness and safety of oral mexiletine administered in monotherapy or in combination with other antiarrhythmic drugs for recurrent ventricular arrhythmia (ventricular tachycardia/ventricular fibrillation, VT/VF) in adult patients with structural heart disease (SHD) and implantable cardioverter defibrillators (ICDs). We systematically searched MEDLINE, Embase, and CENTRAL databases from inception to 27 August 2021 for prospective and retrospective studies investigating mexiletine in the target population. The main outcome was the reduction of ICD therapy. The main safety outcome was the presence of any serious adverse events (SAEs) leading to mexiletine discontinuation. Study quality was assessed using the Cochrane risk of bias tool or the Newcastle-Ottawa scale. Four studies comprising 86 mexiletine recipients were included in the review. We also obtained individual data of 50 patients from two studies. Ischaemic cardiomyopathy (ICM) was present in 86% of patients. The quality of included studies was moderate/low. A narrative review was undertaken as studies varied widely in terms of study population and treatment. Across studies, mexiletine treatment (with or without amiodarone) seemed to consistently reduce the number of ICD therapies especially in a population where catheter ablation (CA) was unsuccessful or contraindicated. In ICM patients deemed eligible for CA, mexiletine seemed to be inferior to CA. Mexiletine was discontinued in 14% of cases, mainly for gastrointestinal or neurological SAE. Mexiletine seems to be an option for the long-term treatment of recurrent VT/VF in adult patients with SHD, especially ICM, and ICD in whom CA was unsuccessful or not suitable.


Assuntos
Amiodarona , Ablação por Cateter , Desfibriladores Implantáveis , Taquicardia Ventricular , Adulto , Antiarrítmicos/efeitos adversos , Desfibriladores Implantáveis/efeitos adversos , Humanos , Mexiletina/efeitos adversos , Estudos Prospectivos , Estudos Retrospectivos , Taquicardia Ventricular/tratamento farmacológico , Taquicardia Ventricular/terapia , Resultado do Tratamento , Fibrilação Ventricular
3.
Cardiology ; 142(1): 4-6, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30852576

RESUMO

The uptake of sacubitril/valsartan since the PARADIGM study confirmed its beneficial effects on outcomes over enalapril in chronic systolic heart failure has inevitably led to potential interactions with co-prescribed medications in real-world patients. We report two cases that raise the possibility of an interaction between sacubitril/valsartan and the class Ib anti-arrhythmic mexiletine resulting in proarrhythmic effects. We discuss the pharmacokinetics of both agents and posit potential mechanistic interactions that suggest caution should be used and careful monitoring for (ventricular) arrhythmias applied in patients receiving sacubitril/valsartan and mexiletine.


Assuntos
Aminobutiratos/efeitos adversos , Antagonistas de Receptores de Angiotensina/efeitos adversos , Arritmias Cardíacas/induzido quimicamente , Mexiletina/efeitos adversos , Tetrazóis/efeitos adversos , Idoso , Aminobutiratos/farmacocinética , Antagonistas de Receptores de Angiotensina/farmacocinética , Compostos de Bifenilo , Combinação de Medicamentos , Interações Medicamentosas , Feminino , Insuficiência Cardíaca Sistólica/tratamento farmacológico , Humanos , Masculino , Mexiletina/farmacocinética , Tetrazóis/farmacocinética , Valsartana
4.
J Cardiovasc Electrophysiol ; 29(4): 603-608, 2018 04.
Artigo em Inglês | MEDLINE | ID: mdl-29356207

RESUMO

INTRODUCTION: In patients with ischemic heart disease and ventricular tachycardia (VT) refractory to high dose amiodarone, the two most common therapeutic options are adjunctive mexiletine therapy or catheter ablation. There are little existing data on the efficacy of these strategies. We examined the relative efficacy of adjunctive mexiletine and catheter ablation among patients enrolled in the VANISH trial. METHODS: All subjects enrolled in the VANISH trial who had VT refractory to high dose (≥ 300 mg daily) amiodarone at baseline were included. Per protocol, subjects randomized to escalated drug therapy received adjunctive mexiletine. RESULTS: Nineteen of the 259 patients were receiving high-dose amiodarone at baseline and 11 were randomized to escalated therapy with mexiletine and 8 to ablation. The adjunctive mexiletine group had a higher rate of the primary composite outcome (death, VT storm, or appropriate shock) in comparison to catheter ablation (HR 6.87 [2.08-22.8]). Over 90% of the patients in the adjunctive mexiletine/group experienced a primary endpoint during a median 9.2 months' follow-up. There was no difference in the rate of adverse events between the two groups. CONCLUSIONS: Mexiletine has limited efficacy in the treatment of recurrent VT despite high-dose amiodarone therapy, in patients with ischemic heart disease. Catheter ablation is a superior strategy in this population.


Assuntos
Amiodarona/administração & dosagem , Antiarrítmicos/administração & dosagem , Ablação por Cateter , Substituição de Medicamentos , Frequência Cardíaca/efeitos dos fármacos , Mexiletina/administração & dosagem , Isquemia Miocárdica/complicações , Taquicardia Ventricular/cirurgia , Potenciais de Ação/efeitos dos fármacos , Idoso , Amiodarona/efeitos adversos , Antiarrítmicos/efeitos adversos , Ablação por Cateter/efeitos adversos , Feminino , Humanos , Masculino , Mexiletina/efeitos adversos , Pessoa de Meia-Idade , Isquemia Miocárdica/diagnóstico , Taquicardia Ventricular/diagnóstico , Taquicardia Ventricular/etiologia , Taquicardia Ventricular/fisiopatologia , Fatores de Tempo , Falha de Tratamento
5.
JAMA ; 320(22): 2344-2353, 2018 12 11.
Artigo em Inglês | MEDLINE | ID: mdl-30535218

RESUMO

Importance: In rare diseases it is difficult to achieve high-quality evidence of treatment efficacy because of small cohorts and clinical heterogeneity. With emerging treatments for rare diseases, innovative trial designs are needed. Objective: To investigate the effectiveness of mexiletine in nondystrophic myotonia using an aggregated N-of-1 trials design and compare results between this innovative design and a previously conducted RCT. Design, Setting, and Participants: A series of aggregated, double-blind, randomized, placebo-controlled N-of-1-trials, performed in a single academic referral center. Thirty Dutch adult patients with genetically confirmed nondystrophic myotonia (38 patients screened) were enrolled between February 2014 and June 2015. Follow-up was completed in September 2016. Interventions: Mexiletine (600 mg daily) vs placebo during multiple treatment periods of 4 weeks. Main Outcomes and Measures: Reduction in daily-reported muscle stiffness on a scale of 1 to 9, with higher scores indicating more impairment. A Bayesian hierarchical model aggregated individual N-of-1 trial data to determine the posterior probability of reaching a clinically meaningful effect of a greater than 0.75-point difference. Results: Among 30 enrolled patients (mean age, 43.4 [SD, 15.24] years; 22% men; 19 CLCN1 and 11 SCN4A genotype), 27 completed the study and 3 dropped out (1 because of a serious adverse event). In 24 of the 27 completers, a clinically meaningful treatment effect was found. In the Bayesian hierarchical model, mexiletine resulted in a 100% posterior probability of reaching a clinically meaningful reduction in self-reported muscle stiffness for the nondystrophic myotonia group overall and the CLCN1 genotype subgroup and 93% posterior probability for the SCN4A genotype subgroup. In the total nondystrophic myotonia group, the median muscle stiffness score was 6.08 (interquartile range, 4.71-6.80) at baseline and was 2.50 (95% credible interval [CrI], 1.77-3.24) during the mexiletine period and 5.56 (95% CrI, 4.73-6.39) during the placebo period; difference in symptom score reduction, 3.06 (95% CrI, 1.96-4.15; n = 27) favoring mexiletine. The most common adverse event was gastrointestinal discomfort (21 mexiletine [70%], 1 placebo [3%]). One serious adverse event occurred (1 mexiletine [3%]; allergic skin reaction). Using frequentist reanalysis, mexiletine compared with placebo resulted in a mean reduction in daily-reported muscle stiffness of 3.12 (95% CI, 2.46-3.78), consistent with the previous RCT treatment effect of 2.69 (95% CI, 2.12-3.26). Conclusions and Relevance: In a series of N-of-1 trials of mexiletine vs placebo in patients with nondystrophic myotonia, there was a reduction in mean daily-reported muscle stiffness that was consistent with the treatment effect in a previous randomized clinical trial. These findings support the efficacy of mexiletine for treatment of nondystrophic myotonia as well as the feasibility of N-of-1 trials for assessing interventions in some chronic rare diseases. Trial Registration: ClinicalTrials.gov Identifier: NCT02045667.


Assuntos
Mexiletina/uso terapêutico , Miotonia/tratamento farmacológico , Transtornos Miotônicos/tratamento farmacológico , Bloqueadores do Canal de Sódio Disparado por Voltagem/uso terapêutico , Adulto , Teorema de Bayes , Método Duplo-Cego , Feminino , Humanos , Masculino , Mexiletina/efeitos adversos , Modelos Estatísticos , Ensaios Clínicos Controlados Aleatórios como Assunto , Doenças Raras , Bloqueadores do Canal de Sódio Disparado por Voltagem/efeitos adversos
6.
Neurochem Res ; 41(5): 1185-91, 2016 May.
Artigo em Inglês | MEDLINE | ID: mdl-26738990

RESUMO

Using the mouse maximal electroshock test, the reference model of tonic-clonic seizures, the aim of the present study was to determine the type of interaction between mexiletine (a class IB antiarrhythmic drug) and classical antiepileptics: valproate, carbamazepine, phenytoin, and phenobarbital. Isobolographic analysis of obtained data indicated antagonistic interactions between mexiletine and valproate (for fixed ratio combinations of 1:1 and 3:1). Additivity was observed between mexiletine and valproate applied in proportion of 1:3 as well as between mexiletine and remaining antiepileptics for the fixed ratios of 1:3, 1:1, and 3:1. Neither motor performance nor long-term memory were impaired by mexiletine or antiepileptic drugs regardless of whether they were administered singly or in combination. Mexiletine did not significantly affected brain concentrations of carbamazepine, phenobarbital or phenytoin. In contrast, the antiarrhythmic drug decreased by 23 % the brain level of valproate. This could be, at least partially, the reason of antagonistic interaction between the two drugs. In conclusion, the observed additivity suggests that mexiletine can be safely applied in epileptic patients treated with carbamazepine, phenytoin or phenobarbital. Because of undesirable pharmacodynamics and pharmacokinetic interactions with valproate, mexiletine should not be used in such combinations.


Assuntos
Anticonvulsivantes/efeitos adversos , Mexiletina/efeitos adversos , Animais , Anticonvulsivantes/farmacocinética , Aprendizagem da Esquiva/efeitos dos fármacos , Encéfalo/metabolismo , Carbamazepina/efeitos adversos , Carbamazepina/farmacocinética , Interações Medicamentosas , Eletrochoque , Masculino , Memória de Longo Prazo/efeitos dos fármacos , Mexiletina/farmacocinética , Camundongos , Atividade Motora/efeitos dos fármacos , Fenobarbital/efeitos adversos , Fenobarbital/farmacocinética , Fenitoína/efeitos adversos , Fenitoína/farmacocinética , Convulsões/tratamento farmacológico , Convulsões/etiologia , Convulsões/fisiopatologia , Distribuição Tecidual , Ácido Valproico/efeitos adversos , Ácido Valproico/farmacocinética
8.
Arch Cardiovasc Dis ; 117(6-7): 450-456, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38677940

RESUMO

In France, mexiletine - a class I antiarrhythmic drug - can be prescribed for the symptomatic treatment of myotonia of the skeletal muscles in adult patients with myotonic dystrophy under a compassionate use programme. Mexiletine is used according to its summary of product characteristics, which describes its use for myotonia treatment in adult patients with non-dystrophic myotonia, a different neuromuscular condition without cardiac involvement. A cardiac assessment is required prior to initiation and throughout treatment due to potential proarrhythmic effects. The presence of conduction system disease, the most common cardiac manifestation of myotonic dystrophy, mandates repeated cardiac evaluations in patients with this condition, and becomes even more important when they are given mexiletine. A group of experts, including three neurologists and five cardiologists from French neuromuscular reference centres, were involved in a task force to develop a treatment algorithm to guide mexiletine use in myotonic dystrophy. The recommendations are based on data from a literature review of the safety of mexiletine-treated patients with myotonic dystrophy, the compassionate use protocol for mexiletine and the personal clinical experience of the experts. The main conclusion of the expert group is that, although existing safety data in mexiletine-treated patients with myotonic dystrophy are reassuring, cardiac assessments should be reinforced in such patients compared with mexiletine-treated patients with non-dystrophic myotonia. This expert opinion to guide mexiletine treatment in patients with myotonic dystrophy should help to reduce the risk of severe adverse events and facilitate interactions between specialists involved in the routine care of patients with myotonic dystrophy.


Assuntos
Mexiletina , Distrofia Miotônica , Adulto , Humanos , Algoritmos , Antiarrítmicos/uso terapêutico , Antiarrítmicos/efeitos adversos , Arritmias Cardíacas/fisiopatologia , Arritmias Cardíacas/diagnóstico , Arritmias Cardíacas/etiologia , Arritmias Cardíacas/induzido quimicamente , Tomada de Decisão Clínica , Ensaios de Uso Compassivo , Consenso , França , Mexiletina/uso terapêutico , Mexiletina/efeitos adversos , Distrofia Miotônica/tratamento farmacológico , Distrofia Miotônica/diagnóstico , Distrofia Miotônica/fisiopatologia , Medição de Risco , Fatores de Risco , Resultado do Tratamento , Bloqueadores do Canal de Sódio Disparado por Voltagem/uso terapêutico , Bloqueadores do Canal de Sódio Disparado por Voltagem/efeitos adversos
9.
J Cardiovasc Pharmacol ; 62(2): 199-204, 2013 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-23609328

RESUMO

The most effective pharmacological management of frequent ventricular tachyarrhythmia events in patients with an implantable defibrillator who failed or did not tolerate amiodarone is unknown. The aim of this retrospective cohort study was to assess the efficacy and tolerability of mexiletine in such patients. The patients served as self-controls. The number of treated ventricular tachyarrhythmia episodes (primary outcome); mortality, shocks from the defibrillator, and electrical storm events (secondary outcomes) during mexiletine therapy was compared with a matched duration of observation just before initiating mexiletine in 29 patients who were treated with a median dose of 300 mg/d of mexiletine and were followed for a median of 12 months. None of the patients had to stop mexiletine due to side effect. There was a significant reduction in the incidence of ventricular tachycardia/fibrillation episodes (median 2 vs. 12 events, P = 0.001) and shocks (median 0 vs. 2 events, P = 0.003) in the first 3 months of treatment, but long-term efficacy was only observed among patients who continued amiodarone therapy. In conclusion, mexiletine, when added to amiodarone in case of amiodarone inefficacy, reduces ventricular tachycardia/fibrillation events and appropriate therapies in patients with an implantable cardioverter defibrillator. A randomized trial should validate the efficacy and safety of mexiletine as an adjunctive therapy to amiodarone.


Assuntos
Amiodarona/uso terapêutico , Antiarrítmicos/uso terapêutico , Desfibriladores Implantáveis/efeitos adversos , Cardiopatias/tratamento farmacológico , Mexiletina/uso terapêutico , Taquicardia Ventricular/prevenção & controle , Adulto , Idoso , Idoso de 80 Anos ou mais , Amiodarona/efeitos adversos , Antiarrítmicos/efeitos adversos , Cardiomiopatias/tratamento farmacológico , Cardiomiopatias/mortalidade , Cardiomiopatias/terapia , Estudos de Coortes , Terapia Combinada , Monitoramento de Medicamentos , Quimioterapia Combinada/efeitos adversos , Feminino , Seguimentos , Cardiopatias/mortalidade , Cardiopatias/terapia , Humanos , Incidência , Masculino , Mexiletina/efeitos adversos , Pessoa de Meia-Idade , Ontário/epidemiologia , Estudos Retrospectivos , Taquicardia Ventricular/epidemiologia
10.
Turk J Pediatr ; 65(4): 704-706, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-37661688

RESUMO

BACKGROUND: Mexiletine, a class IB antiarrhythmic, is a structural analog of lidocaine. Our knowledge of mexiletine overdose is based on lidocaine overdose reports. Only a few cases of mexiletine overdose have been reported, including fatal overdoses. Mexiletine toxicity primarily affects the central nervous, cardiovascular, and gastrointestinal systems. CASE: A 16-year-old female was brought to our hospital by ambulance after taking an unknown dose of mexiletine in a suicide attempt. Ventricular fibrillation developed while in the ambulance; cardiopulmonary resuscitation was started and spontaneous circulation returned within 1 min. The patient had been taking oral mexiletine for 1 month to treat primary erythromelalgia. Her vital signs were normal, but she was unconscious. Following gastric lavage she was transferred to the pediatric intensive care unit. Midazolam and levetiracetam were required due to uncontrolled seizures. During the first hour of hospitalization, severe dyskinesia characterized by abnormal involuntary large hyperkinetic movements in all 4 extremities was observed and successfully treated with 2 doses of intravenous biperiden. The patient was discharged on day 6 of hospitalization. CONCLUSIONS: Mexiletine overdose can be life-threatening. In addition to rapid and effective resuscitation, rapid identification and management of cardiovascular and central nervous system manifestations are key to preventing morbidity and mortality. The presented case had severe dyskinesia that was successfully treated with repeated doses of biperiden. Biperiden did not cause arrhythmia. Based on the presented case, we think biperiden should be considered for the treatment of movement disorders in cases of mexiletine overdose.


Assuntos
Discinesias , Eritromelalgia , Mexiletina , Humanos , Discinesias/tratamento farmacológico , Discinesias/etiologia , Mexiletina/efeitos adversos , Mexiletina/uso terapêutico , Feminino , Adolescente , Antiarrítmicos/efeitos adversos , Antiarrítmicos/uso terapêutico , Overdose de Drogas , Eritromelalgia/tratamento farmacológico , Biperideno/administração & dosagem , Resultado do Tratamento
11.
Circ Res ; 106(8): 1374-83, 2010 Apr 30.
Artigo em Inglês | MEDLINE | ID: mdl-20339117

RESUMO

RATIONALE: Sodium channel blockers are used as gene-specific treatments in long-QT syndrome type 3, which is caused by mutations in the sodium channel gene (SCN5A). Response to treatment is influenced by biophysical properties of mutations. OBJECTIVE: We sought to investigate the unexpected deleterious effect of mexiletine in a mutation combining gain-of- function and trafficking abnormalities. METHODS AND RESULTS: A long-QT syndrome type 3 child experienced paradoxical QT prolongation and worsening of arrhythmias after mexiletine treatment. The SCN5A mutation F1473S expressed in HEK293 cells presented a right-ward shift of steady-state inactivation, enlarged window current, and huge sustained sodium current. Unexpectedly, it also reduced the peak sodium current by 80%. Immunostaining showed that mutant Nav1.5 is retained in the cytoplasm. Incubation with 10 micromol/L mexiletine rescued the trafficking defect of F1473S, causing a significant increase in peak current, whereas sustained current was unchanged. Using a Markovian model of the Na channel and a model of human ventricular action potential, we showed that simulated exposure of F1473S to mexiletine paradoxically increased action potential duration, mimicking QT prolongation seen in the index patient on mexiletine treatment. CONCLUSIONS: Sodium channel blockers are largely used to shorten QT intervals in carriers of SCN5A mutations. We provided evidence that these agents may facilitate trafficking of mutant proteins, thus exacerbating QT prolongation. These data suggest that caution should be used when recommending this class of drugs to carriers of mutations with undefined electrophysiological properties.


Assuntos
Antiarrítmicos/efeitos adversos , Ativação do Canal Iônico/efeitos dos fármacos , Síndrome do QT Longo/tratamento farmacológico , Mexiletina/efeitos adversos , Proteínas Musculares/antagonistas & inibidores , Mutação , Bloqueadores dos Canais de Sódio/efeitos adversos , Potenciais de Ação , Linhagem Celular , Simulação por Computador , Eletrocardiografia , Evolução Fatal , Predisposição Genética para Doença , Humanos , Lactente , Ativação do Canal Iônico/genética , Cinética , Síndrome do QT Longo/genética , Síndrome do QT Longo/metabolismo , Masculino , Cadeias de Markov , Modelos Cardiovasculares , Proteínas Musculares/genética , Proteínas Musculares/metabolismo , Canal de Sódio Disparado por Voltagem NAV1.5 , Fenótipo , Transporte Proteico , Canais de Sódio/genética , Canais de Sódio/metabolismo , Transfecção , Resultado do Tratamento
12.
Klin Padiatr ; 224(5): 309-12, 2012 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-22170168

RESUMO

Erythromelalgia is a rare disorder characterized by recurrent pain attacks, swelling and redness in the distal extremities. The primary forms of the disorder are caused by mutations in voltage-gated sodium channels. Treatment is difficult and controlled therapeutic studies offer little to no guidance. We report on a 12-year-old boy and his first occurrence of primary erythromelalgia. Genetic findings for mutations in the SCN9A gene, which encodes for the α-subunit of sodium channel NaV1.7, were negative. Although initial treatment with sodium nitroprusside was ineffective, subsequent medication with lidocaine and mexiletine, in combination with gabapentin, was successful. Despite negative findings for mutations in the sodium channels, the use of sodium channel blockers should be considered in these patients.


Assuntos
Análise Mutacional de DNA , Eritromelalgia/tratamento farmacológico , Eritromelalgia/genética , Canal de Sódio Disparado por Voltagem NAV1.7/genética , Bloqueadores dos Canais de Sódio/uso terapêutico , Administração Oral , Aminas/efeitos adversos , Aminas/uso terapêutico , Analgésicos/efeitos adversos , Analgésicos/uso terapêutico , Criança , Ácidos Cicloexanocarboxílicos/efeitos adversos , Ácidos Cicloexanocarboxílicos/uso terapêutico , Diagnóstico Diferencial , Relação Dose-Resposta a Droga , Quimioterapia Combinada , Eritromelalgia/diagnóstico , Gabapentina , Humanos , Infusões Intravenosas , Lidocaína/efeitos adversos , Lidocaína/uso terapêutico , Masculino , Mexiletina/efeitos adversos , Mexiletina/uso terapêutico , Nitroprussiato/efeitos adversos , Nitroprussiato/uso terapêutico , Bloqueadores dos Canais de Sódio/efeitos adversos , Resultado do Tratamento , Vasodilatadores/efeitos adversos , Vasodilatadores/uso terapêutico , Ácido gama-Aminobutírico/efeitos adversos , Ácido gama-Aminobutírico/uso terapêutico
13.
JAMA ; 308(13): 1357-65, 2012 Oct 03.
Artigo em Inglês | MEDLINE | ID: mdl-23032552

RESUMO

CONTEXT: Nondystrophic myotonias (NDMs) are rare diseases caused by mutations in skeletal muscle ion channels. Patients experience delayed muscle relaxation causing functionally limiting stiffness and pain. Mexiletine-induced sodium channel blockade reduced myotonia in small studies; however, as is common in rare diseases, larger studies of safety and efficacy have not previously been considered feasible. OBJECTIVE: To determine the effects of mexiletine for symptoms and signs of myotonia in patients with NDMs. DESIGN, SETTING, AND PARTICIPANTS: A randomized, double-blind, placebo-controlled 2-period crossover study at 7 neuromuscular referral centers in 4 countries of 59 patients with NDMs conducted between December 23, 2008, and March 30, 2011, as part of the National Institutes of Health-funded Rare Disease Clinical Research Network. INTERVENTION: Oral 200-mg mexiletine or placebo capsules 3 times daily for 4 weeks, followed by the opposite intervention for 4 weeks, with 1-week washout in between. MAIN OUTCOME MEASURES: Patient-reported severity score of stiffness recorded on an interactive voice response (IVR) diary (scale of 1 = minimal to 9 = worst ever experienced). Secondary end points included IVR-reported changes in pain, weakness, and tiredness; clinical myotonia assessment; quantitative measure of handgrip myotonia; and Individualized Neuromuscular Quality of Life summary quality of life score (INQOL-QOL, percentage of maximal detrimental impact). RESULTS: Mexiletine significantly improved patient-reported severity score stiffness on the IVR diary. Because of a statistically significant interaction between treatment and period for this outcome, primary end point is presented by period (period 1 means were 2.53 for mexiletine and 4.21 for placebo; difference, -1.68; 95% CI, -2.66 to -0.706; P < .001; period 2 means were 1.60 for mexiletine and 5.27 for placebo; difference, -3.68; 95% CI, -3.85 to -0.139; P = .04). Mexiletine improved the INQOL-QOL score (mexiletine, 14.0 vs placebo, 16.7; difference, -2.69; 95% CI, -4.07 to -1.30; P < .001) and decreased handgrip myotonia on clinical examination (mexiletine, 0.164 seconds vs placebo, 0.494 seconds; difference, -0.330; 95% CI, -0.633 to -0.142; P < .001). The most common adverse effect was gastrointestinal (9 mexiletine and 1 placebo). Two participants experienced transient cardiac effects that did not require stopping the study (1 in each group). One serious adverse event was determined to be not study related. CONCLUSION: In this preliminary study of patients with NDMs, the use of mexiletine compared with placebo resulted in improved patient-reported stiffness over 4 weeks of treatment, despite some concern about the maintenance of blinding. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00832000.


Assuntos
Antiarrítmicos/uso terapêutico , Mexiletina/uso terapêutico , Miotonia/tratamento farmacológico , Administração Oral , Adolescente , Adulto , Idoso , Antiarrítmicos/efeitos adversos , Estudos Cross-Over , Método Duplo-Cego , Feminino , Humanos , Masculino , Mexiletina/efeitos adversos , Pessoa de Meia-Idade , Músculo Esquelético/fisiopatologia , Dor/tratamento farmacológico , Dor/etiologia , Qualidade de Vida , Índice de Gravidade de Doença , Canais de Sódio/efeitos dos fármacos , Adulto Jovem
14.
Am J Otolaryngol ; 32(2): 168-70, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-20392536

RESUMO

Erythromelalgia is a rare condition characterized by burning pain, erythema, swelling, and increased temperature usually in the extremities. We present an unusual presentation of erythromelalgia of the ears in a patient who has been refractory to multiple therapies and in whom relief of symptoms was achieved with the use of mexiletine. A review of clinical presentation, pathophysiology, and therapeutic options are presented.


Assuntos
Fármacos Dermatológicos/uso terapêutico , Otopatias/tratamento farmacológico , Eritromelalgia/tratamento farmacológico , Mexiletina/uso terapêutico , Fármacos Dermatológicos/efeitos adversos , Otopatias/fisiopatologia , Orelha Externa , Eritromelalgia/fisiopatologia , Humanos , Masculino , Mexiletina/efeitos adversos , Pessoa de Meia-Idade , Resultado do Tratamento
15.
Pharmacol Res Perspect ; 9(4): e00828, 2021 08.
Artigo em Inglês | MEDLINE | ID: mdl-34327875

RESUMO

Prolongation of the cardiac action potential (AP) and early after depolarizations (EADs) are electrical anomalies of cardiomyocytes that can lead to lethal arrhythmias and are potential liabilities for existing drugs and drug candidates in development. For example, long QT syndrome-3 (LQTS3) is caused by mutations in the Nav 1.5 sodium channel that debilitate channel inactivation and cause arrhythmias. We tested the hypothesis that a useful drug (i.e., mexiletine) with potential liabilities (i.e., potassium channel inhibition and adverse reactions) could be re-engineered by dynamic medicinal chemistry to afford a new drug candidate with greater efficacy and less toxicity. Human cardiomyocytes were generated from LQTS3 patient-derived induced pluripotent stem cells (hIPSCs) and normal hIPSCs to determine beneficial (on-target) and detrimental effects (off-target) of mexiletine and synthetic analogs, respectively. The approach combined "drug discovery" and "hit to lead" refinement and showed that iterations of medicinal chemistry and physiological testing afforded optimized compound 22. Compared to mexiletine, compound 22 showed a 1.85-fold greater AUC and no detectable CNS toxicity at 100 mg/kg. In vitro hepatic metabolism studies showed that 22 was metabolized via cytochrome P-450, as previously shown, and by the flavin-containing monooxygenase (FMO). Deuterated-22 showed decreased metabolism and showed acceptable cardiovascular and physicochemical properties.


Assuntos
Células-Tronco Pluripotentes Induzidas/citologia , Mexiletina/análogos & derivados , Mexiletina/farmacocinética , Miócitos Cardíacos/metabolismo , Animais , Comportamento Animal/efeitos dos fármacos , Células Cultivadas , Feminino , Humanos , Fígado/metabolismo , Síndrome do QT Longo , Masculino , Mexiletina/efeitos adversos , Camundongos Endogâmicos BALB C , Ratos Sprague-Dawley , Convulsões/induzido quimicamente
16.
J Korean Med Sci ; 25(1): 148-51, 2010 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-20052362

RESUMO

An 82-yr-old man was presented with fever and cough accompanied by generalized erythematous rash. He had taken mexiletine for 5 months, as he had been diagnosed with dilated cardiomyopathy and ventricular arrhythmia. Laboratory studies showed peripheral blood eosinophilia and elevated liver transaminase levels. Chest radiographs showed multiple nodular consolidations in both lungs. Biopsies of the lung and skin lesions revealed eosinophilic infiltration. After a thorough review of his medication history, mexiletine was suspected as the etiologic agent. After discontinuing the mexiletine and starting oral prednisolone, the patient improved, and the skin and lung lesions disappeared. Subsequently, mexiletine was confirmed as the causative agent based on a positive patch test. Drug-induced hypersensitivity syndrome is a severe adverse reaction to drugs and results from treatment with anticonvulsants, allopurinol, sulfonamides, and many other drugs. Several cases of mexiletine-induced hypersensitivity syndrome have been reported in older Japanese males with manifestation of fever, rash, peripheral blood eosinophilia, liver dysfunction without other organ involvement. Here, we report a case of mexiletine-induced hypersensitivity syndrome which presented as eosinophilic pneumonia in a Korean male.


Assuntos
Antiarrítmicos/efeitos adversos , Hipersensibilidade a Drogas/diagnóstico , Mexiletina/efeitos adversos , Eosinofilia Pulmonar/induzido quimicamente , Eosinofilia Pulmonar/diagnóstico , Idoso de 80 Anos ou mais , Arritmias Cardíacas/tratamento farmacológico , Cardiomiopatia Dilatada/tratamento farmacológico , Hipersensibilidade a Drogas/etiologia , Exantema/patologia , Humanos , Pulmão/diagnóstico por imagem , Pulmão/patologia , Masculino , Síndrome , Tomografia Computadorizada por Raios X
17.
Sci Rep ; 10(1): 8397, 2020 05 21.
Artigo em Inglês | MEDLINE | ID: mdl-32439959

RESUMO

The 'translational therapeutic index' (TTI) is a drug's ratio of nonclinical threshold dose (or concentration) for significant benefit versus threshold for adversity. In early nonclinical research, discovery and safety studies are normally undertaken separately. Our aim was to evaluate a novel integrated approach for generating a TTI for drugs intended for prevention of ischaemia-induced ventricular fibrillation (VF). We templated the current best available class 1b antiarrhythmic, mexiletine, using the rat Langendorff preparation. Mexiletine's beneficial effects on the incidence of VF caused by 120 min regional ischaemia were contrasted with its concurrent adverse effects (on several variables) in the same hearts, to generate a TTI. Mexiletine 0.1 and 0.5 µM had no adverse effects, but did not reduce VF incidence. Mexiletine 1 µM reduced VF incidence to 0% but had adverse effects on atrioventricular conduction and ventricular repolarization. Separate studies undertaken using an intraventricular balloon revealed no detrimental effects of mexiletine (1 and 5 µM) on mechanical function, or any benefit against reperfusion-related dysfunction. Mexiletine's TTI was found to be less than two, which accords with its clinical therapeutic index. Although non-cardiac adversity, identifiable from additional in vivo studies, may reduce the TTI further, it cannot increase it. Our experimental approach represents a useful early-stage integrated risk/benefit method that, when TTI is found to be low, would eliminate unsuitable class 1b drugs prior to next stage in vivo work, with mexiletine's TTI defining the gold standard that would need to be bettered.


Assuntos
Antiarrítmicos/farmacologia , Mexiletina/farmacologia , Isquemia Miocárdica/complicações , Fibrilação Ventricular/tratamento farmacológico , Animais , Antiarrítmicos/administração & dosagem , Antiarrítmicos/efeitos adversos , Relação Dose-Resposta a Droga , Eletrocardiografia , Coração/efeitos dos fármacos , Masculino , Mexiletina/administração & dosagem , Mexiletina/efeitos adversos , Isquemia Miocárdica/fisiopatologia , Técnicas de Cultura de Órgãos , Ratos Wistar , Fibrilação Ventricular/etiologia
18.
Anesthesiology ; 109(2): 289-96, 2008 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-18648238

RESUMO

BACKGROUND: Stump and phantom pains are debilitating sequelae of amputations that are often resistant to treatment. The efficacy of pharmacologic therapies, including opioids and sodium channel blockers, for postamputation pain is uncertain. METHODS: The authors conducted a double-blind, randomized, placebo-controlled, crossover study in adult patients with postamputation pain of 6 months or longer and greater than 3 on a 0-10 numeric pain rating scale. Each of the three treatment periods (morphine, mexiletine, or placebo) included a 1-week drug-free interval followed by 4-week titration, 2-week maintenance, and 2-week drug-taper phases. The primary outcome measure was change in average pain intensity from the drug-free baseline to the last week of maintenance. RESULTS: Sixty amputees were enrolled; data were analyzed from 56 subjects for one drug period, 45 subjects for two drug periods, and 35 subjects who completed all three drug periods. The mean morphine and mexiletine dosages were 112 and 933 mg, respectively. Morphine treatment provided lower pain scores compared with placebo and mexiletine (P = 0.0003). The mean percent pain relief during treatment with placebo, mexiletine, and morphine was 19, 30, and 53%, respectively (P < 0.0001, morphine vs. placebo and mexiletine). The numbers needed to treat to obtain 50% and 33% decreases in pain intensity with morphine were 5.6 and 4.5, respectively. Treatment with morphine was associated with a higher rate of side effects. CONCLUSIONS: Therapy with morphine, but not mexiletine, resulted in a decrease in intensity of postamputation pain but was associated with a higher rate of side effects and no improvement in self-reported levels of overall functional activity and pain-related interference in daily activities.


Assuntos
Amputação Cirúrgica , Antiarrítmicos/uso terapêutico , Mexiletina/uso terapêutico , Morfina/uso terapêutico , Dor Pós-Operatória/tratamento farmacológico , Membro Fantasma/tratamento farmacológico , Antiarrítmicos/efeitos adversos , Estudos Cross-Over , Relação Dose-Resposta a Droga , Método Duplo-Cego , Feminino , Humanos , Masculino , Mexiletina/efeitos adversos , Pessoa de Meia-Idade , Morfina/efeitos adversos , Dor Pós-Operatória/classificação , Membro Fantasma/classificação , Membro Fantasma/etiologia
19.
Headache ; 48(10): 1506-10, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-18793209

RESUMO

OBJECTIVE: To describe the use of mexiletine in the treatment of chronic daily headache in a refractory headache population. BACKGROUND: Intravenous lidocaine is a novel treatment for chronic daily headache with medication overuse and SUNCT syndrome. Mexiletine is a similar but orally active anti-arrhythmic that has been demonstrated to be an effective analgesic in various types of neuropathic pain. We looked at mexiletine as a preventative treatment for headache in refractory patients. METHODS: We reviewed the medical records of all patients with an order for mexiletine. For each patient, we determined diagnosis, presence of medication overuse on initial evaluation, pain scores, and if the patient received intravenous lidocaine before starting the medication. We then contacted patients by phone to confirm their dose, to review side effects and current pain scores, and to obtain a global impression of effectiveness. RESULTS: We identified 9 patients with a chronic daily headache, including chronic migraine or new daily persistent headache, with significant clinical improvement while using mexiletine as a headache preventative. Each patient had failed to respond to multiple preventative and acute treatments. Seven of the 9 rated mexiletine "much more effective" and 2 "more effective" than previous preventative headache medications. The daily dose ranged from 600 mg/day to 1500 mg/day. Side effects were common and occurred in 7 patients. The majority of patients with an order for mexiletine did not respond to treatment or had intolerable side effects. DISCUSSION: The preliminary study suggests mexiletine is a useful preventative treatment for some patients with chronic daily headache, including refractory patients with medication overuse or those who have failed multiple preventatives in the past.


Assuntos
Transtornos da Cefaleia/tratamento farmacológico , Mexiletina/administração & dosagem , Adulto , Analgésicos/administração & dosagem , Analgésicos/efeitos adversos , Antiarrítmicos/administração & dosagem , Antiarrítmicos/efeitos adversos , Anticonvulsivantes/administração & dosagem , Anticonvulsivantes/efeitos adversos , Relação Dose-Resposta a Droga , Esquema de Medicação , Resistência a Medicamentos/efeitos dos fármacos , Feminino , Transtornos da Cefaleia Secundários/tratamento farmacológico , Humanos , Masculino , Mexiletina/efeitos adversos , Pessoa de Meia-Idade , Estudos Retrospectivos , Resultado do Tratamento , Adulto Jovem
20.
Pain Physician ; 21(5): E573-E579, 2018 09.
Artigo em Inglês | MEDLINE | ID: mdl-30282405

RESUMO

BACKGROUND: Intravenous lidocaine has multiple applications in the management of acute and chronic pain. Mexiletine, an oral lidocaine analogue, has been used in a number of chronic pain conditions although its use is not well characterized. OBJECTIVES: To report our experience using mexiletine in a chronic pain population, specifically looking at tolerability, side effects, and EKG changes. STUDY DESIGN: Retrospective, cohort study. SETTING: Three chronic pain clinics within a hospital system in Detroit, MI. METHODS: All patients who had a mexiletine prescription between August 2015 and August 2016 were queried via the electronic medical record. Each chart was examined for demographics, QTc changes on EKG, length of use, and reasons for stoppage. RESULTS: There were 74 total patients identified in the chronic pain management clinics as receiving at least 1 mexiletine prescription over the 1-year time period. Twice as many women as men received mexiletine prescriptions. Neuropathic pain was the most common primary diagnosis (64%) which included diabetic neuropathy, radiculopathy, and others. Fibromyalgia was the next most common primary diagnosis (28%). A QTc change on the EKG showed a mean decrease of 0.1 ms and median increase of 1.5 ms. At 6 months (180 days), approximately 30% of the patients remained on mexiletine therapy, and 28% remained on the therapy at 1 year (360 days). Median duration of use was 60 days and the mean was 288 days. Neurologic and gastrointestinal side effects were the most commons reason for stoppage. All side effects were mild and resolved with stoppage. After side effects, lack of response, or loss of efficacy, were the next most common reasons for stoppage. LIMITATIONS: Pain relief and outcomes were not specifically examined due to confounding factors including interventional treatments and multiple treatment modalities. This was a retrospective, cohort study limited to our specific clinic population with a relatively high loss to follow-up rate. CONCLUSION: Mexiletine is rarely a first line option for chronic pain management and is often used when multiple other modalities have failed. By reporting our experience, we hope other clinicians may have more familiarity with the drug's use in a chronic pain practice. It appears reasonably tolerable, may not require frequent EKG monitoring, and can be an appropriate adjunct in the chronic pain population. More research is needed regarding efficacy and dose titration for mexiletine in chronic pain. KEY WORDS: Chronic pain, mexiletine, IV lidocaine, pain, neuropathic pain, neuropathy, fibromyalgia, QTc, tolerability.


Assuntos
Analgésicos/administração & dosagem , Dor Crônica/tratamento farmacológico , Mexiletina/efeitos adversos , Estudos de Coortes , Feminino , Humanos , Masculino , Estudos Retrospectivos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA